organization · Reporting owner
Wellington Biomedical Innovation Master Investors (Cayman) I L.P.
Disclosed activity across 16 companies
Sign in to followReported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Boundless Bio, Inc.BOLD · Entity 7063 | 10% owner | April 02, 2024 | April 03, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Boundless Bio, Inc.
Report date April 02, 2024 · Filed April 03, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 556,233 |
Ending reported balance
After 2024-04-02 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2024-04-02 · Conversion · Acquired 189,933 · Balance 189,933 F1: On April 2, 2024, the Series B Preferred Stock automatically converted into Common Stock on a 19.5-for-1 basis without payment of further consideration upon the closing of the initial public offering of the Issuer's common stock. The Series B Preferred Stock had no expiration date. Row 2 · 2024-04-02 · Conversion · Acquired 366,300 · Balance 556,233 F2: On April 2, 2024, the Series C Preferred Stock automatically converted into Common Stock on a 19.5-for-1 basis without payment of further consideration upon the closing of the initial public offering of the Issuer's common stock. The Series C Preferred Stock had no expiration date. |
| Series B Preferred StockSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2024-04-02 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2024-04-02 · Conversion · Disposed 3,703,704 · Balance 0 F1: On April 2, 2024, the Series B Preferred Stock automatically converted into Common Stock on a 19.5-for-1 basis without payment of further consideration upon the closing of the initial public offering of the Issuer's common stock. The Series B Preferred Stock had no expiration date. |
| Series C Preferred StockSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2024-04-02 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2024-04-02 · Conversion · Disposed 7,142,857 · Balance 0 F2: On April 2, 2024, the Series C Preferred Stock automatically converted into Common Stock on a 19.5-for-1 basis without payment of further consideration upon the closing of the initial public offering of the Issuer's common stock. The Series C Preferred Stock had no expiration date. |
Filing footnotes · ownership attribution and instrument terms
F1: On April 2, 2024, the Series B Preferred Stock automatically converted into Common Stock on a 19.5-for-1 basis without payment of further consideration upon the closing of the initial public offering of the Issuer's common stock. The Series B Preferred Stock had no expiration date.
F2: On April 2, 2024, the Series C Preferred Stock automatically converted into Common Stock on a 19.5-for-1 basis without payment of further consideration upon the closing of the initial public offering of the Issuer's common stock. The Series C Preferred Stock had no expiration date.
Past disclosures · reporting ended (15)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Acrivon Therapeutics, Inc.
Report date November 17, 2022 · Filed November 21, 2022
Section 16 reporting ended · disclosed 2022-11-21. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 888,130 |
Reported balance
After 2022-11-17 transaction · row 1
1 source rowRow 1 · 2022-11-17 · Conversion · Acquired 888,130 · Balance 888,130 F1: On November 17, 2022, the Series B Preferred Stock automatically converted into Common Stock on a 1-to-2.466 basis without payment of further consideration upon the closing of the initial public offering of the Issuer's common stock. The Series B Preferred Stock had no expiration date. |
| Series B Preferred StockSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2022-11-17 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2022-11-17 · Conversion · Disposed 2,190,131 · Balance 0 F1: On November 17, 2022, the Series B Preferred Stock automatically converted into Common Stock on a 1-to-2.466 basis without payment of further consideration upon the closing of the initial public offering of the Issuer's common stock. The Series B Preferred Stock had no expiration date. |
Filing footnotes · ownership attribution and instrument terms
F1: On November 17, 2022, the Series B Preferred Stock automatically converted into Common Stock on a 1-to-2.466 basis without payment of further consideration upon the closing of the initial public offering of the Issuer's common stock. The Series B Preferred Stock had no expiration date.
Aligos Therapeutics, Inc.
Report date October 20, 2020 · Filed October 22, 2020
Section 16 reporting ended · disclosed 2020-10-22. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 1,906,191 |
Ending reported balance
After 2020-10-20 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2020-10-20 · Conversion · Acquired 1,335,048 · Balance 1,335,048 F1: The shares of series B-1 convertible preferred stock and series B-2 convertible preferred stock shall automatically convert into shares of Common Stock on a one to one basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and have no expiration date. Row 2 · 2020-10-20 · Conversion · Acquired 571,143 · Balance 1,906,191 F1: The shares of series B-1 convertible preferred stock and series B-2 convertible preferred stock shall automatically convert into shares of Common Stock on a one to one basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and have no expiration date. |
| Series B-1 convertible Preferred StockSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2020-10-20 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2020-10-20 · Conversion · Disposed 1,335,048 · Balance 0 F1: The shares of series B-1 convertible preferred stock and series B-2 convertible preferred stock shall automatically convert into shares of Common Stock on a one to one basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and have no expiration date. |
| Series B-2 convertible Preferred StockSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2020-10-20 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2020-10-20 · Conversion · Disposed 571,143 · Balance 0 F1: The shares of series B-1 convertible preferred stock and series B-2 convertible preferred stock shall automatically convert into shares of Common Stock on a one to one basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and have no expiration date. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares of series B-1 convertible preferred stock and series B-2 convertible preferred stock shall automatically convert into shares of Common Stock on a one to one basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and have no expiration date.
Artiva Biotherapeutics, Inc.
Report date July 22, 2024 · Filed July 23, 2024
Section 16 reporting ended · disclosed 2024-07-23. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 194,108 |
Ending reported balance
After 2024-07-22 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2024-07-22 · Conversion · Acquired 145,089 · Balance 145,089 F1: Each share of Series B Preferred Stock converted into shares of Common Stock of the Issuer on a one-for-one basis without payment of further consideration. Upon the closing of the Issuer's initial public offering (the "IPO"), the Series B Preferred Stock was converted into the number of shares of Common Stock of the Issuer shown in column 7 of Table II. The Series B Preferred Stock had no expiration date. Row 2 · 2024-07-22 · Other · Acquired 49,019 · Balance 194,108 F2: Represents the conversion of outstanding simple agreement for future equity in the amount of $500,000.00 into shares of the Issuer's common stock upon closing of the Issuer's IPO at a 15% discount to the IPO price. |
| Series B Preferred StockSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2024-07-22 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2024-07-22 · Conversion · Disposed 145,089 · Balance 0 F1: Each share of Series B Preferred Stock converted into shares of Common Stock of the Issuer on a one-for-one basis without payment of further consideration. Upon the closing of the Issuer's initial public offering (the "IPO"), the Series B Preferred Stock was converted into the number of shares of Common Stock of the Issuer shown in column 7 of Table II. The Series B Preferred Stock had no expiration date. |
Filing footnotes · ownership attribution and instrument terms
F1: Each share of Series B Preferred Stock converted into shares of Common Stock of the Issuer on a one-for-one basis without payment of further consideration. Upon the closing of the Issuer's initial public offering (the "IPO"), the Series B Preferred Stock was converted into the number of shares of Common Stock of the Issuer shown in column 7 of Table II. The Series B Preferred Stock had no expiration date.
F2: Represents the conversion of outstanding simple agreement for future equity in the amount of $500,000.00 into shares of the Issuer's common stock upon closing of the Issuer's IPO at a 15% discount to the IPO price.
Black Diamond Therapeutics, Inc.
Report date February 03, 2020 · Filed February 05, 2020
Section 16 reporting ended · disclosed 2020-02-05. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 568,185 |
Reported balance
After 2020-02-03 transaction · row 1
1 source rowRow 1 · 2020-02-03 · Conversion · Acquired 568,185 · Balance 568,185 F1: Upon the closing of the Issuer's initial public offering, all shares of Series C Preferred Stock automatically converted into shares of Common Stock of the Issuer on a one-for-3.01581 basis. The Series C Preferred Stock had no expiration date. |
| Series C Preferred StockSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2020-02-03 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2020-02-03 · Conversion · Disposed 1,713,541 · Balance 0 F1: Upon the closing of the Issuer's initial public offering, all shares of Series C Preferred Stock automatically converted into shares of Common Stock of the Issuer on a one-for-3.01581 basis. The Series C Preferred Stock had no expiration date. |
Filing footnotes · ownership attribution and instrument terms
F1: Upon the closing of the Issuer's initial public offering, all shares of Series C Preferred Stock automatically converted into shares of Common Stock of the Issuer on a one-for-3.01581 basis. The Series C Preferred Stock had no expiration date.
Dyne Therapeutics, Inc.
Report date September 21, 2020 · Filed September 23, 2020
Section 16 reporting ended · disclosed 2020-09-23. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 1,608,785 |
Reported balance
After 2020-09-21 transaction · row 1
1 source rowRow 1 · 2020-09-21 · Conversion · Acquired 1,608,785 · Balance 1,608,785 F1: On September 21, 2020, the Series B Preferred Stock automatically converted into Common Stock on a 3.3169-for-one basis without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date. |
| Series B Preferred StockSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2020-09-21 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2020-09-21 · Conversion · Disposed 5,336,179 · Balance 0 F1: On September 21, 2020, the Series B Preferred Stock automatically converted into Common Stock on a 3.3169-for-one basis without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date. |
Filing footnotes · ownership attribution and instrument terms
F1: On September 21, 2020, the Series B Preferred Stock automatically converted into Common Stock on a 3.3169-for-one basis without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date.
Edgewise Therapeutics, Inc.
Report date March 30, 2021 · Filed March 30, 2021
Section 16 reporting ended · disclosed 2021-03-30. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 681,812 |
Reported balance
After 2021-03-30 transaction · row 1
1 source rowRow 1 · 2021-03-30 · Conversion · Acquired 681,812 · Balance 681,812 F1: Upon the closing of the Issuer's initial public offering, each share of Series C Preferred Stock automatically converted into one share of the Issuer's Common Stock. The Series C Preferred Stock had no expiration date. |
| Series C Preferred StockSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2021-03-30 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2021-03-30 · Conversion · Disposed 681,812 · Balance 0 F1: Upon the closing of the Issuer's initial public offering, each share of Series C Preferred Stock automatically converted into one share of the Issuer's Common Stock. The Series C Preferred Stock had no expiration date. |
Filing footnotes · ownership attribution and instrument terms
F1: Upon the closing of the Issuer's initial public offering, each share of Series C Preferred Stock automatically converted into one share of the Issuer's Common Stock. The Series C Preferred Stock had no expiration date.
Forma Therapeutics Holdings, Inc.
Report date June 23, 2020 · Filed June 25, 2020
Section 16 reporting ended · disclosed 2020-06-25. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 2,252,913 |
Ending reported balance
After 2020-06-23 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2020-06-23 · Conversion · Acquired 1,252,913 · Balance 1,252,913 F1: On June 23, 2020, the Series D Convertible Preferred Stock automatically converted into common stock on a 4.2775-for-one basis without payment of further consideration upon the closing of the initial public offering of the Issuer's common stock. The shares had no expiration date. Row 2 · 2020-06-23 · Purchase · Acquired 1,000,000 · Balance 2,252,913 |
| Series D Convertible Preferred StockSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2020-06-23 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2020-06-23 · Conversion · Disposed 5,359,344 · Balance 0 F1: On June 23, 2020, the Series D Convertible Preferred Stock automatically converted into common stock on a 4.2775-for-one basis without payment of further consideration upon the closing of the initial public offering of the Issuer's common stock. The shares had no expiration date. |
Filing footnotes · ownership attribution and instrument terms
F1: On June 23, 2020, the Series D Convertible Preferred Stock automatically converted into common stock on a 4.2775-for-one basis without payment of further consideration upon the closing of the initial public offering of the Issuer's common stock. The shares had no expiration date.
Generation Bio Co.
Report date June 16, 2020 · Filed June 18, 2020
Section 16 reporting ended · disclosed 2020-06-18. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 2,112,546 |
Ending reported balance
After 2020-06-16 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2020-06-16 · Conversion · Acquired 1,012,546 · Balance 1,012,546 F1: On June 16, 2020, the Series C Preferred Stock automatically converted into Common Stock on a 1.7663-for-one basis without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date. Row 2 · 2020-06-16 · Purchase · Acquired 1,100,000 · Balance 2,112,546 |
| Series C Preferred StockSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2020-06-16 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2020-06-16 · Conversion · Disposed 1,788,460 · Balance 0 F1: On June 16, 2020, the Series C Preferred Stock automatically converted into Common Stock on a 1.7663-for-one basis without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date. |
Filing footnotes · ownership attribution and instrument terms
F1: On June 16, 2020, the Series C Preferred Stock automatically converted into Common Stock on a 1.7663-for-one basis without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date.
Kymera Therapeutics, Inc.
Report date August 25, 2020 · Filed August 27, 2020
Section 16 reporting ended · disclosed 2020-08-27. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 959,211 |
Reported balance
After 2020-08-25 transaction · row 1
1 source rowRow 1 · 2020-08-25 · Conversion · Acquired 959,211 · Balance 959,211 F1: Upon the closing of the Issuer's initial public offering, each share of Series C Preferred Stock automatically converted into shares of the Issuer's Common Stock on a 1.5949-for-one basis. The Series C Preferred Stock had no expiration date. |
| Series C Preferred StockSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2020-08-25 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2020-08-25 · Conversion · Disposed 1,529,847 · Balance 0 F1: Upon the closing of the Issuer's initial public offering, each share of Series C Preferred Stock automatically converted into shares of the Issuer's Common Stock on a 1.5949-for-one basis. The Series C Preferred Stock had no expiration date. |
Filing footnotes · ownership attribution and instrument terms
F1: Upon the closing of the Issuer's initial public offering, each share of Series C Preferred Stock automatically converted into shares of the Issuer's Common Stock on a 1.5949-for-one basis. The Series C Preferred Stock had no expiration date.
Nurix Therapeutics, Inc.
Report date July 28, 2020 · Filed July 31, 2020
Section 16 reporting ended · disclosed 2020-07-31. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 784,313 |
Reported balance
After 2020-07-28 transaction · row 1
1 source rowRow 1 · 2020-07-28 · Conversion · Acquired 784,313 · Balance 784,313 F1: Immediately prior to the closing of the Issuer's initial public offering, each share of Series D Preferred Stock automatically converted into one share of Common Stock of the Issuer. The Series D Preferred Stock had no expiration date. |
| Series D Preferred StockSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2020-07-28 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2020-07-28 · Conversion · Disposed 784,313 · Balance 0 F1: Immediately prior to the closing of the Issuer's initial public offering, each share of Series D Preferred Stock automatically converted into one share of Common Stock of the Issuer. The Series D Preferred Stock had no expiration date. |
Filing footnotes · ownership attribution and instrument terms
F1: Immediately prior to the closing of the Issuer's initial public offering, each share of Series D Preferred Stock automatically converted into one share of Common Stock of the Issuer. The Series D Preferred Stock had no expiration date.
Nuvalent, Inc.
Report date August 02, 2021 · Filed August 04, 2021
Section 16 reporting ended · disclosed 2021-08-04. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class A Common StockSEC Table I · non-derivative | Direct | 897,671 |
Reported balance
After 2021-08-02 transaction · row 1
1 source rowRow 1 · 2021-08-02 · Conversion · Acquired 897,671 · Balance 897,671 F1: Upon the closing of the Issuer's initial public offering, each share of Series B Preferred Stock automatically converted into 0.1858 shares of the Issuer's Class A Common Stock. The Series B Preferred Stock had no expiration date. |
| Series B Preferred StockSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2021-08-02 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2021-08-02 · Conversion · Disposed 4,831,384 · Balance 0 F1: Upon the closing of the Issuer's initial public offering, each share of Series B Preferred Stock automatically converted into 0.1858 shares of the Issuer's Class A Common Stock. The Series B Preferred Stock had no expiration date. |
Filing footnotes · ownership attribution and instrument terms
F1: Upon the closing of the Issuer's initial public offering, each share of Series B Preferred Stock automatically converted into 0.1858 shares of the Issuer's Class A Common Stock. The Series B Preferred Stock had no expiration date.
Olema Pharmaceuticals, Inc.
Report date November 23, 2020 · Filed November 24, 2020
Section 16 reporting ended · disclosed 2020-11-24. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 1,725,406 |
Ending reported balance
After 2020-11-23 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2020-11-23 · Conversion · Acquired 1,273,420 · Balance 1,273,420 F1: Upon the closing of the Issuer's initial public offering, each share of Series B Preferred Stock and Series C Preferred Stock automatically converted into one share of the Issuer's Common Stock. Each of the Series B Preferred Stock and Series C Preferred Stock had no expiration date. Row 2 · 2020-11-23 · Conversion · Acquired 451,986 · Balance 1,725,406 F1: Upon the closing of the Issuer's initial public offering, each share of Series B Preferred Stock and Series C Preferred Stock automatically converted into one share of the Issuer's Common Stock. Each of the Series B Preferred Stock and Series C Preferred Stock had no expiration date. |
| Series B Preferred StockSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2020-11-23 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2020-11-23 · Conversion · Disposed 1,273,420 · Balance 0 F1: Upon the closing of the Issuer's initial public offering, each share of Series B Preferred Stock and Series C Preferred Stock automatically converted into one share of the Issuer's Common Stock. Each of the Series B Preferred Stock and Series C Preferred Stock had no expiration date. |
| Series C Preferred StockSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2020-11-23 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2020-11-23 · Conversion · Disposed 451,986 · Balance 0 F1: Upon the closing of the Issuer's initial public offering, each share of Series B Preferred Stock and Series C Preferred Stock automatically converted into one share of the Issuer's Common Stock. Each of the Series B Preferred Stock and Series C Preferred Stock had no expiration date. |
Filing footnotes · ownership attribution and instrument terms
F1: Upon the closing of the Issuer's initial public offering, each share of Series B Preferred Stock and Series C Preferred Stock automatically converted into one share of the Issuer's Common Stock. Each of the Series B Preferred Stock and Series C Preferred Stock had no expiration date.
PMV Pharmaceuticals, Inc.
Report date September 29, 2020 · Filed September 29, 2020
Section 16 reporting ended · disclosed 2020-09-29. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 760,267 |
Reported balance
After 2020-09-29 transaction · row 1
1 source rowRow 1 · 2020-09-29 · Conversion · Acquired 760,267 · Balance 760,267 F1: The shares of Series D Preferred Stock automatically converted into shares of Common Stock on a one to one basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and have no expiration date. |
| Series D Preferred StockSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2020-09-29 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2020-09-29 · Conversion · Disposed 760,267 · Balance 0 F1: The shares of Series D Preferred Stock automatically converted into shares of Common Stock on a one to one basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and have no expiration date. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares of Series D Preferred Stock automatically converted into shares of Common Stock on a one to one basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and have no expiration date.
Verve Therapeutics, Inc.
Report date June 21, 2021 · Filed June 22, 2021
Section 16 reporting ended · disclosed 2021-06-22. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 2,495,571 |
Ending reported balance
After 2021-06-21 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2021-06-21 · Conversion · Acquired 1,343,081 · Balance 1,343,081 F1: The Series A-2 Preferred Stock converted into shares of the Issuer's common stock, $0.001 par value, on an approximately 9.2595:1 basis automatically immediately prior to the closing of the Issuer's initial public offering. The Series A-2 Preferred Stock had no expiration date. Row 2 · 2021-06-21 · Conversion · Acquired 1,152,490 · Balance 2,495,571 F2: The Series B Preferred Stock converted into shares of the Issuer's common stock, $0.001 par value, on an approximately 9.2595:1 basis automatically immediately prior to the closing of the Issuer's initial public offering. The Series B Preferred Stock had no expiration date. |
| Series A-2 Preferred StockSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2021-06-21 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2021-06-21 · Conversion · Disposed 12,436,264 · Balance 0 F1: The Series A-2 Preferred Stock converted into shares of the Issuer's common stock, $0.001 par value, on an approximately 9.2595:1 basis automatically immediately prior to the closing of the Issuer's initial public offering. The Series A-2 Preferred Stock had no expiration date. |
| Series B Preferred StockSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2021-06-21 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2021-06-21 · Conversion · Disposed 10,671,482 · Balance 0 F2: The Series B Preferred Stock converted into shares of the Issuer's common stock, $0.001 par value, on an approximately 9.2595:1 basis automatically immediately prior to the closing of the Issuer's initial public offering. The Series B Preferred Stock had no expiration date. |
Filing footnotes · ownership attribution and instrument terms
F1: The Series A-2 Preferred Stock converted into shares of the Issuer's common stock, $0.001 par value, on an approximately 9.2595:1 basis automatically immediately prior to the closing of the Issuer's initial public offering. The Series A-2 Preferred Stock had no expiration date.
F2: The Series B Preferred Stock converted into shares of the Issuer's common stock, $0.001 par value, on an approximately 9.2595:1 basis automatically immediately prior to the closing of the Issuer's initial public offering. The Series B Preferred Stock had no expiration date.
Zenas BioPharma, Inc.
Report date September 16, 2024 · Filed September 18, 2024
Section 16 reporting ended · disclosed 2024-09-18. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 801,624 |
Ending reported balance
After 2024-09-16 transaction · row 3
3 source rows · reconciled sequenceRow 1 · 2024-09-16 · Conversion · Acquired 180,635 · Balance 180,635 F1: On September 16, 2024, the shares of Series A Convertible Preferred Stock automatically converted into shares of Common Stock on a 8.6831-for-1 basis without payment of further consideration upon the closing of the Issuer's initial public offering. The shares have no expiration date. Row 2 · 2024-09-16 · Conversion · Acquired 420,271 · Balance 600,906 F2: On September 16, 2024, the shares of Series B Convertible Preferred Stock automatically converted into shares of Common Stock on a 8.6831-for-1 basis without payment of further consideration upon the closing of the Issuer's initial public offering. The shares have no expiration date. F1: On September 16, 2024, the shares of Series A Convertible Preferred Stock automatically converted into shares of Common Stock on a 8.6831-for-1 basis without payment of further consideration upon the closing of the Issuer's initial public offering. The shares have no expiration date. Row 3 · 2024-09-16 · Conversion · Acquired 200,718 · Balance 801,624 F2: On September 16, 2024, the shares of Series B Convertible Preferred Stock automatically converted into shares of Common Stock on a 8.6831-for-1 basis without payment of further consideration upon the closing of the Issuer's initial public offering. The shares have no expiration date. F1: On September 16, 2024, the shares of Series A Convertible Preferred Stock automatically converted into shares of Common Stock on a 8.6831-for-1 basis without payment of further consideration upon the closing of the Issuer's initial public offering. The shares have no expiration date. |
| Series A Convertible Preferred StockSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2024-09-16 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2024-09-16 · Conversion · Disposed 1,568,480 · Balance 0 F1: On September 16, 2024, the shares of Series A Convertible Preferred Stock automatically converted into shares of Common Stock on a 8.6831-for-1 basis without payment of further consideration upon the closing of the Issuer's initial public offering. The shares have no expiration date. |
| Series B Convertible Preferred StockSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2024-09-16 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2024-09-16 · Conversion · Disposed 3,649,263 · Balance 0 F2: On September 16, 2024, the shares of Series B Convertible Preferred Stock automatically converted into shares of Common Stock on a 8.6831-for-1 basis without payment of further consideration upon the closing of the Issuer's initial public offering. The shares have no expiration date. |
| Series C Convertible Preferred StockSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2024-09-16 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2024-09-16 · Conversion · Disposed 1,742,858 · Balance 0 F3: On September 16, 2024, the shares of Series C Convertible Preferred Stock automatically converted into shares of Common Stock on a 8.6831-for-1 basis without payment of further consideration upon the closing of the Issuer's initial public offering. The shares have no expiration date. |
Filing footnotes · ownership attribution and instrument terms
F1: On September 16, 2024, the shares of Series A Convertible Preferred Stock automatically converted into shares of Common Stock on a 8.6831-for-1 basis without payment of further consideration upon the closing of the Issuer's initial public offering. The shares have no expiration date.
F2: On September 16, 2024, the shares of Series B Convertible Preferred Stock automatically converted into shares of Common Stock on a 8.6831-for-1 basis without payment of further consideration upon the closing of the Issuer's initial public offering. The shares have no expiration date.
F3: On September 16, 2024, the shares of Series C Convertible Preferred Stock automatically converted into shares of Common Stock on a 8.6831-for-1 basis without payment of further consideration upon the closing of the Issuer's initial public offering. The shares have no expiration date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 16, 2024 Filed Sep 18, 2024 17:16 UTC | Zenas BioPharma, Inc. ZBIO · Entity 275 | ConversionSeries C Convertible Preferred Stock · Derivative | 1,742,858 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-24-101030 · tm2424157-11_4seq1.xml · derivative · entry 6 Wellington Biomedical Innovation Master Investors (Cayman) I L.P. · CIK 0001787092 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 200,718 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: On September 16, 2024, the shares of Series C Convertible Preferred Stock automatically converted into shares of Common Stock on a 8.6831-for-1 basis without payment of further consideration upon the closing of the Issuer's initial public offering. The shares have no expiration date. F3 · price: On September 16, 2024, the shares of Series C Convertible Preferred Stock automatically converted into shares of Common Stock on a 8.6831-for-1 basis without payment of further consideration upon the closing of the Issuer's initial public offering. The shares have no expiration date. F3 · derivative.exercise_date: On September 16, 2024, the shares of Series C Convertible Preferred Stock automatically converted into shares of Common Stock on a 8.6831-for-1 basis without payment of further consideration upon the closing of the Issuer's initial public offering. The shares have no expiration date. F3 · derivative.expiration_date: On September 16, 2024, the shares of Series C Convertible Preferred Stock automatically converted into shares of Common Stock on a 8.6831-for-1 basis without payment of further consideration upon the closing of the Issuer's initial public offering. The shares have no expiration date. Read SEC document |
| September 16, 2024 Filed Sep 18, 2024 17:16 UTC | Zenas BioPharma, Inc. ZBIO · Entity 275 | ConversionSeries B Convertible Preferred Stock · Derivative | 3,649,263 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-24-101030 · tm2424157-11_4seq1.xml · derivative · entry 5 Wellington Biomedical Innovation Master Investors (Cayman) I L.P. · CIK 0001787092 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 420,271 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: On September 16, 2024, the shares of Series B Convertible Preferred Stock automatically converted into shares of Common Stock on a 8.6831-for-1 basis without payment of further consideration upon the closing of the Issuer's initial public offering. The shares have no expiration date. F2 · price: On September 16, 2024, the shares of Series B Convertible Preferred Stock automatically converted into shares of Common Stock on a 8.6831-for-1 basis without payment of further consideration upon the closing of the Issuer's initial public offering. The shares have no expiration date. F2 · derivative.exercise_date: On September 16, 2024, the shares of Series B Convertible Preferred Stock automatically converted into shares of Common Stock on a 8.6831-for-1 basis without payment of further consideration upon the closing of the Issuer's initial public offering. The shares have no expiration date. F2 · derivative.expiration_date: On September 16, 2024, the shares of Series B Convertible Preferred Stock automatically converted into shares of Common Stock on a 8.6831-for-1 basis without payment of further consideration upon the closing of the Issuer's initial public offering. The shares have no expiration date. Read SEC document |
| September 16, 2024 Filed Sep 18, 2024 17:16 UTC | Zenas BioPharma, Inc. ZBIO · Entity 275 | ConversionSeries A Convertible Preferred Stock · Derivative | 1,568,480 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-24-101030 · tm2424157-11_4seq1.xml · derivative · entry 4 Wellington Biomedical Innovation Master Investors (Cayman) I L.P. · CIK 0001787092 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 180,635 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: On September 16, 2024, the shares of Series A Convertible Preferred Stock automatically converted into shares of Common Stock on a 8.6831-for-1 basis without payment of further consideration upon the closing of the Issuer's initial public offering. The shares have no expiration date. F1 · price: On September 16, 2024, the shares of Series A Convertible Preferred Stock automatically converted into shares of Common Stock on a 8.6831-for-1 basis without payment of further consideration upon the closing of the Issuer's initial public offering. The shares have no expiration date. F1 · derivative.exercise_date: On September 16, 2024, the shares of Series A Convertible Preferred Stock automatically converted into shares of Common Stock on a 8.6831-for-1 basis without payment of further consideration upon the closing of the Issuer's initial public offering. The shares have no expiration date. F1 · derivative.expiration_date: On September 16, 2024, the shares of Series A Convertible Preferred Stock automatically converted into shares of Common Stock on a 8.6831-for-1 basis without payment of further consideration upon the closing of the Issuer's initial public offering. The shares have no expiration date. Read SEC document |
| September 16, 2024 Filed Sep 18, 2024 17:16 UTC | Zenas BioPharma, Inc. ZBIO · Entity 275 | ConversionCommon Stock | 200,718 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-24-101030 · tm2424157-11_4seq1.xml · nonDerivative · entry 3 Wellington Biomedical Innovation Master Investors (Cayman) I L.P. · CIK 0001787092 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 801,624 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · kind: On September 16, 2024, the shares of Series B Convertible Preferred Stock automatically converted into shares of Common Stock on a 8.6831-for-1 basis without payment of further consideration upon the closing of the Issuer's initial public offering. The shares have no expiration date. F1 · price: On September 16, 2024, the shares of Series A Convertible Preferred Stock automatically converted into shares of Common Stock on a 8.6831-for-1 basis without payment of further consideration upon the closing of the Issuer's initial public offering. The shares have no expiration date. Read SEC document |
| September 16, 2024 Filed Sep 18, 2024 17:16 UTC | Zenas BioPharma, Inc. ZBIO · Entity 275 | ConversionCommon Stock | 420,271 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-24-101030 · tm2424157-11_4seq1.xml · nonDerivative · entry 2 Wellington Biomedical Innovation Master Investors (Cayman) I L.P. · CIK 0001787092 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 600,906 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · kind: On September 16, 2024, the shares of Series B Convertible Preferred Stock automatically converted into shares of Common Stock on a 8.6831-for-1 basis without payment of further consideration upon the closing of the Issuer's initial public offering. The shares have no expiration date. F1 · price: On September 16, 2024, the shares of Series A Convertible Preferred Stock automatically converted into shares of Common Stock on a 8.6831-for-1 basis without payment of further consideration upon the closing of the Issuer's initial public offering. The shares have no expiration date. Read SEC document |
| September 16, 2024 Filed Sep 18, 2024 17:16 UTC | Zenas BioPharma, Inc. ZBIO · Entity 275 | ConversionCommon Stock | 180,635 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-24-101030 · tm2424157-11_4seq1.xml · nonDerivative · entry 1 Wellington Biomedical Innovation Master Investors (Cayman) I L.P. · CIK 0001787092 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 180,635 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: On September 16, 2024, the shares of Series A Convertible Preferred Stock automatically converted into shares of Common Stock on a 8.6831-for-1 basis without payment of further consideration upon the closing of the Issuer's initial public offering. The shares have no expiration date. F1 · price: On September 16, 2024, the shares of Series A Convertible Preferred Stock automatically converted into shares of Common Stock on a 8.6831-for-1 basis without payment of further consideration upon the closing of the Issuer's initial public offering. The shares have no expiration date. Read SEC document |
| July 22, 2024 Filed Jul 23, 2024 00:28 UTC | Artiva Biotherapeutics, Inc. ARTV · Entity 5404 | ConversionSeries B Preferred Stock · Derivative | 145,089 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-24-019908 · form4-07232024_120714.xml · derivative · entry 3 Wellington Biomedical Innovation Master Investors (Cayman) I L.P. · CIK 0001787092 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 145,089 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of Series B Preferred Stock converted into shares of Common Stock of the Issuer on a one-for-one basis without payment of further consideration. Upon the closing of the Issuer's initial public offering (the "IPO"), the Series B Preferred Stock was converted into the number of shares of Common Stock of the Issuer shown in column 7 of Table II. The Series B Preferred Stock had no expiration date. F1 · price: Each share of Series B Preferred Stock converted into shares of Common Stock of the Issuer on a one-for-one basis without payment of further consideration. Upon the closing of the Issuer's initial public offering (the "IPO"), the Series B Preferred Stock was converted into the number of shares of Common Stock of the Issuer shown in column 7 of Table II. The Series B Preferred Stock had no expiration date. F1 · derivative.exercise_date: Each share of Series B Preferred Stock converted into shares of Common Stock of the Issuer on a one-for-one basis without payment of further consideration. Upon the closing of the Issuer's initial public offering (the "IPO"), the Series B Preferred Stock was converted into the number of shares of Common Stock of the Issuer shown in column 7 of Table II. The Series B Preferred Stock had no expiration date. F1 · derivative.expiration_date: Each share of Series B Preferred Stock converted into shares of Common Stock of the Issuer on a one-for-one basis without payment of further consideration. Upon the closing of the Issuer's initial public offering (the "IPO"), the Series B Preferred Stock was converted into the number of shares of Common Stock of the Issuer shown in column 7 of Table II. The Series B Preferred Stock had no expiration date. Read SEC document |
| July 22, 2024 Filed Jul 23, 2024 00:28 UTC | Artiva Biotherapeutics, Inc. ARTV · Entity 5404 | OtherCommon Stock | 49,019 | $10.20 | $499,993.80 |
DisclosureSEC source: 0001415889-24-019908 · form4-07232024_120714.xml · nonDerivative · entry 2 Wellington Biomedical Innovation Master Investors (Cayman) I L.P. · CIK 0001787092 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 194,108 F2 · kind: Represents the conversion of outstanding simple agreement for future equity in the amount of $500,000.00 into shares of the Issuer's common stock upon closing of the Issuer's IPO at a 15% discount to the IPO price. Read SEC document |
| July 22, 2024 Filed Jul 23, 2024 00:28 UTC | Artiva Biotherapeutics, Inc. ARTV · Entity 5404 | ConversionCommon Stock | 145,089 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-24-019908 · form4-07232024_120714.xml · nonDerivative · entry 1 Wellington Biomedical Innovation Master Investors (Cayman) I L.P. · CIK 0001787092 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 145,089 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each share of Series B Preferred Stock converted into shares of Common Stock of the Issuer on a one-for-one basis without payment of further consideration. Upon the closing of the Issuer's initial public offering (the "IPO"), the Series B Preferred Stock was converted into the number of shares of Common Stock of the Issuer shown in column 7 of Table II. The Series B Preferred Stock had no expiration date. Read SEC document |
| April 02, 2024 Filed Apr 3, 2024 00:42 UTC | Boundless Bio, Inc. BOLD · Entity 7063 | ConversionSeries C Preferred Stock · Derivative | 7,142,857 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-009885 · form4-04032024_120459.xml · derivative · entry 4 Wellington Biomedical Innovation Master Investors (Cayman) I L.P. · CIK 0001787092 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 366,300 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: On April 2, 2024, the Series C Preferred Stock automatically converted into Common Stock on a 19.5-for-1 basis without payment of further consideration upon the closing of the initial public offering of the Issuer's common stock. The Series C Preferred Stock had no expiration date. F2 · derivative.exercise_date: On April 2, 2024, the Series C Preferred Stock automatically converted into Common Stock on a 19.5-for-1 basis without payment of further consideration upon the closing of the initial public offering of the Issuer's common stock. The Series C Preferred Stock had no expiration date. F2 · derivative.expiration_date: On April 2, 2024, the Series C Preferred Stock automatically converted into Common Stock on a 19.5-for-1 basis without payment of further consideration upon the closing of the initial public offering of the Issuer's common stock. The Series C Preferred Stock had no expiration date. Read SEC document |
| April 02, 2024 Filed Apr 3, 2024 00:42 UTC | Boundless Bio, Inc. BOLD · Entity 7063 | ConversionSeries B Preferred Stock · Derivative | 3,703,704 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-009885 · form4-04032024_120459.xml · derivative · entry 3 Wellington Biomedical Innovation Master Investors (Cayman) I L.P. · CIK 0001787092 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 189,933 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: On April 2, 2024, the Series B Preferred Stock automatically converted into Common Stock on a 19.5-for-1 basis without payment of further consideration upon the closing of the initial public offering of the Issuer's common stock. The Series B Preferred Stock had no expiration date. F1 · derivative.exercise_date: On April 2, 2024, the Series B Preferred Stock automatically converted into Common Stock on a 19.5-for-1 basis without payment of further consideration upon the closing of the initial public offering of the Issuer's common stock. The Series B Preferred Stock had no expiration date. F1 · derivative.expiration_date: On April 2, 2024, the Series B Preferred Stock automatically converted into Common Stock on a 19.5-for-1 basis without payment of further consideration upon the closing of the initial public offering of the Issuer's common stock. The Series B Preferred Stock had no expiration date. Read SEC document |
| April 02, 2024 Filed Apr 3, 2024 00:42 UTC | Boundless Bio, Inc. BOLD · Entity 7063 | ConversionCommon Stock | 366,300 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-24-009885 · form4-04032024_120459.xml · nonDerivative · entry 2 Wellington Biomedical Innovation Master Investors (Cayman) I L.P. · CIK 0001787092 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 556,233 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · price: On April 2, 2024, the Series C Preferred Stock automatically converted into Common Stock on a 19.5-for-1 basis without payment of further consideration upon the closing of the initial public offering of the Issuer's common stock. The Series C Preferred Stock had no expiration date. Read SEC document |
| April 02, 2024 Filed Apr 3, 2024 00:42 UTC | Boundless Bio, Inc. BOLD · Entity 7063 | ConversionCommon Stock | 189,933 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-24-009885 · form4-04032024_120459.xml · nonDerivative · entry 1 Wellington Biomedical Innovation Master Investors (Cayman) I L.P. · CIK 0001787092 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 189,933 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: On April 2, 2024, the Series B Preferred Stock automatically converted into Common Stock on a 19.5-for-1 basis without payment of further consideration upon the closing of the initial public offering of the Issuer's common stock. The Series B Preferred Stock had no expiration date. Read SEC document |
| November 17, 2022 Filed Nov 21, 2022 18:22 UTC | Acrivon Therapeutics, Inc. ACRV · Entity 573 | ConversionSeries B Preferred Stock · Derivative | 2,190,131 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-22-025513 · ownership.xml · derivative · entry 2 Wellington Biomedical Innovation Master Investors (Cayman) I L.P. · CIK 0001787092 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 888,130 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: On November 17, 2022, the Series B Preferred Stock automatically converted into Common Stock on a 1-to-2.466 basis without payment of further consideration upon the closing of the initial public offering of the Issuer's common stock. The Series B Preferred Stock had no expiration date. F1 · derivative.exercise_date: On November 17, 2022, the Series B Preferred Stock automatically converted into Common Stock on a 1-to-2.466 basis without payment of further consideration upon the closing of the initial public offering of the Issuer's common stock. The Series B Preferred Stock had no expiration date. F1 · derivative.expiration_date: On November 17, 2022, the Series B Preferred Stock automatically converted into Common Stock on a 1-to-2.466 basis without payment of further consideration upon the closing of the initial public offering of the Issuer's common stock. The Series B Preferred Stock had no expiration date. Read SEC document |
| November 17, 2022 Filed Nov 21, 2022 18:22 UTC | Acrivon Therapeutics, Inc. ACRV · Entity 573 | ConversionCommon Stock | 888,130 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-22-025513 · ownership.xml · nonDerivative · entry 1 Wellington Biomedical Innovation Master Investors (Cayman) I L.P. · CIK 0001787092 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 888,130 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: On November 17, 2022, the Series B Preferred Stock automatically converted into Common Stock on a 1-to-2.466 basis without payment of further consideration upon the closing of the initial public offering of the Issuer's common stock. The Series B Preferred Stock had no expiration date. Read SEC document |
| August 02, 2021 Filed Aug 4, 2021 00:01 UTC | Nuvalent, Inc. NUVL · Entity 29892 | ConversionSeries B Preferred Stock · Derivative | 4,831,384 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-21-031393 · doc4.xml · derivative · entry 2 Wellington Biomedical Innovation Master Investors (Cayman) I L.P. · CIK 0001787092 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Class A Common Stock · 897,671 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Upon the closing of the Issuer's initial public offering, each share of Series B Preferred Stock automatically converted into 0.1858 shares of the Issuer's Class A Common Stock. The Series B Preferred Stock had no expiration date. F1 · derivative.exercise_date: Upon the closing of the Issuer's initial public offering, each share of Series B Preferred Stock automatically converted into 0.1858 shares of the Issuer's Class A Common Stock. The Series B Preferred Stock had no expiration date. F1 · derivative.expiration_date: Upon the closing of the Issuer's initial public offering, each share of Series B Preferred Stock automatically converted into 0.1858 shares of the Issuer's Class A Common Stock. The Series B Preferred Stock had no expiration date. Read SEC document |
| August 02, 2021 Filed Aug 4, 2021 00:01 UTC | Nuvalent, Inc. NUVL · Entity 29892 | ConversionClass A Common Stock | 897,671 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-21-031393 · doc4.xml · nonDerivative · entry 1 Wellington Biomedical Innovation Master Investors (Cayman) I L.P. · CIK 0001787092 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 897,671 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Upon the closing of the Issuer's initial public offering, each share of Series B Preferred Stock automatically converted into 0.1858 shares of the Issuer's Class A Common Stock. The Series B Preferred Stock had no expiration date. Read SEC document |
| June 21, 2021 Filed Jun 22, 2021 17:14 UTC | Verve Therapeutics, Inc. VERV · Entity 11259 | ConversionSeries B Preferred Stock · Derivative | 10,671,482 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-21-025303 · doc4.xml · derivative · entry 4 Wellington Biomedical Innovation Master Investors (Cayman) I L.P. · CIK 0001787092 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,152,490 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: The Series B Preferred Stock converted into shares of the Issuer's common stock, $0.001 par value, on an approximately 9.2595:1 basis automatically immediately prior to the closing of the Issuer's initial public offering. The Series B Preferred Stock had no expiration date. F2 · price: The Series B Preferred Stock converted into shares of the Issuer's common stock, $0.001 par value, on an approximately 9.2595:1 basis automatically immediately prior to the closing of the Issuer's initial public offering. The Series B Preferred Stock had no expiration date. F2 · derivative.exercise_date: The Series B Preferred Stock converted into shares of the Issuer's common stock, $0.001 par value, on an approximately 9.2595:1 basis automatically immediately prior to the closing of the Issuer's initial public offering. The Series B Preferred Stock had no expiration date. F2 · derivative.expiration_date: The Series B Preferred Stock converted into shares of the Issuer's common stock, $0.001 par value, on an approximately 9.2595:1 basis automatically immediately prior to the closing of the Issuer's initial public offering. The Series B Preferred Stock had no expiration date. Read SEC document |
| June 21, 2021 Filed Jun 22, 2021 17:14 UTC | Verve Therapeutics, Inc. VERV · Entity 11259 | ConversionSeries A-2 Preferred Stock · Derivative | 12,436,264 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-21-025303 · doc4.xml · derivative · entry 3 Wellington Biomedical Innovation Master Investors (Cayman) I L.P. · CIK 0001787092 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,343,081 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The Series A-2 Preferred Stock converted into shares of the Issuer's common stock, $0.001 par value, on an approximately 9.2595:1 basis automatically immediately prior to the closing of the Issuer's initial public offering. The Series A-2 Preferred Stock had no expiration date. F1 · price: The Series A-2 Preferred Stock converted into shares of the Issuer's common stock, $0.001 par value, on an approximately 9.2595:1 basis automatically immediately prior to the closing of the Issuer's initial public offering. The Series A-2 Preferred Stock had no expiration date. F1 · derivative.exercise_date: The Series A-2 Preferred Stock converted into shares of the Issuer's common stock, $0.001 par value, on an approximately 9.2595:1 basis automatically immediately prior to the closing of the Issuer's initial public offering. The Series A-2 Preferred Stock had no expiration date. F1 · derivative.expiration_date: The Series A-2 Preferred Stock converted into shares of the Issuer's common stock, $0.001 par value, on an approximately 9.2595:1 basis automatically immediately prior to the closing of the Issuer's initial public offering. The Series A-2 Preferred Stock had no expiration date. Read SEC document |
| June 21, 2021 Filed Jun 22, 2021 17:14 UTC | Verve Therapeutics, Inc. VERV · Entity 11259 | ConversionCommon Stock | 1,152,490 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-21-025303 · doc4.xml · nonDerivative · entry 2 Wellington Biomedical Innovation Master Investors (Cayman) I L.P. · CIK 0001787092 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,495,571 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · price: The Series B Preferred Stock converted into shares of the Issuer's common stock, $0.001 par value, on an approximately 9.2595:1 basis automatically immediately prior to the closing of the Issuer's initial public offering. The Series B Preferred Stock had no expiration date. Read SEC document |
| June 21, 2021 Filed Jun 22, 2021 17:14 UTC | Verve Therapeutics, Inc. VERV · Entity 11259 | ConversionCommon Stock | 1,343,081 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-21-025303 · doc4.xml · nonDerivative · entry 1 Wellington Biomedical Innovation Master Investors (Cayman) I L.P. · CIK 0001787092 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,343,081 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The Series A-2 Preferred Stock converted into shares of the Issuer's common stock, $0.001 par value, on an approximately 9.2595:1 basis automatically immediately prior to the closing of the Issuer's initial public offering. The Series A-2 Preferred Stock had no expiration date. Read SEC document |
| March 30, 2021 Filed Mar 30, 2021 21:12 UTC | Edgewise Therapeutics, Inc. EWTX · Entity 3965 | ConversionSeries C Preferred Stock · Derivative | 681,812 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-21-013928 · doc4.xml · derivative · entry 2 Wellington Biomedical Innovation Master Investors (Cayman) I L.P. · CIK 0001787092 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 681,812 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Upon the closing of the Issuer's initial public offering, each share of Series C Preferred Stock automatically converted into one share of the Issuer's Common Stock. The Series C Preferred Stock had no expiration date. F1 · derivative.exercise_date: Upon the closing of the Issuer's initial public offering, each share of Series C Preferred Stock automatically converted into one share of the Issuer's Common Stock. The Series C Preferred Stock had no expiration date. F1 · derivative.expiration_date: Upon the closing of the Issuer's initial public offering, each share of Series C Preferred Stock automatically converted into one share of the Issuer's Common Stock. The Series C Preferred Stock had no expiration date. Read SEC document |
| March 30, 2021 Filed Mar 30, 2021 21:12 UTC | Edgewise Therapeutics, Inc. EWTX · Entity 3965 | ConversionCommon Stock | 681,812 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-21-013928 · doc4.xml · nonDerivative · entry 1 Wellington Biomedical Innovation Master Investors (Cayman) I L.P. · CIK 0001787092 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 681,812 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Upon the closing of the Issuer's initial public offering, each share of Series C Preferred Stock automatically converted into one share of the Issuer's Common Stock. The Series C Preferred Stock had no expiration date. Read SEC document |
| November 23, 2020 Filed Nov 24, 2020 22:36 UTC | Olema Pharmaceuticals, Inc. OLMA · Entity 613 | ConversionSeries C Preferred Stock · Derivative | 451,986 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-20-032050 · doc4.xml · derivative · entry 4 Wellington Biomedical Innovation Master Investors (Cayman) I L.P. · CIK 0001787092 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 451,986 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Upon the closing of the Issuer's initial public offering, each share of Series B Preferred Stock and Series C Preferred Stock automatically converted into one share of the Issuer's Common Stock. Each of the Series B Preferred Stock and Series C Preferred Stock had no expiration date. F1 · derivative.exercise_date: Upon the closing of the Issuer's initial public offering, each share of Series B Preferred Stock and Series C Preferred Stock automatically converted into one share of the Issuer's Common Stock. Each of the Series B Preferred Stock and Series C Preferred Stock had no expiration date. F1 · derivative.expiration_date: Upon the closing of the Issuer's initial public offering, each share of Series B Preferred Stock and Series C Preferred Stock automatically converted into one share of the Issuer's Common Stock. Each of the Series B Preferred Stock and Series C Preferred Stock had no expiration date. Read SEC document |
| November 23, 2020 Filed Nov 24, 2020 22:36 UTC | Olema Pharmaceuticals, Inc. OLMA · Entity 613 | ConversionSeries B Preferred Stock · Derivative | 1,273,420 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-20-032050 · doc4.xml · derivative · entry 3 Wellington Biomedical Innovation Master Investors (Cayman) I L.P. · CIK 0001787092 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,273,420 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Upon the closing of the Issuer's initial public offering, each share of Series B Preferred Stock and Series C Preferred Stock automatically converted into one share of the Issuer's Common Stock. Each of the Series B Preferred Stock and Series C Preferred Stock had no expiration date. F1 · derivative.exercise_date: Upon the closing of the Issuer's initial public offering, each share of Series B Preferred Stock and Series C Preferred Stock automatically converted into one share of the Issuer's Common Stock. Each of the Series B Preferred Stock and Series C Preferred Stock had no expiration date. F1 · derivative.expiration_date: Upon the closing of the Issuer's initial public offering, each share of Series B Preferred Stock and Series C Preferred Stock automatically converted into one share of the Issuer's Common Stock. Each of the Series B Preferred Stock and Series C Preferred Stock had no expiration date. Read SEC document |
| November 23, 2020 Filed Nov 24, 2020 22:36 UTC | Olema Pharmaceuticals, Inc. OLMA · Entity 613 | ConversionCommon Stock | 451,986 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-20-032050 · doc4.xml · nonDerivative · entry 2 Wellington Biomedical Innovation Master Investors (Cayman) I L.P. · CIK 0001787092 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,725,406 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Upon the closing of the Issuer's initial public offering, each share of Series B Preferred Stock and Series C Preferred Stock automatically converted into one share of the Issuer's Common Stock. Each of the Series B Preferred Stock and Series C Preferred Stock had no expiration date. Read SEC document |
| November 23, 2020 Filed Nov 24, 2020 22:36 UTC | Olema Pharmaceuticals, Inc. OLMA · Entity 613 | ConversionCommon Stock | 1,273,420 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-20-032050 · doc4.xml · nonDerivative · entry 1 Wellington Biomedical Innovation Master Investors (Cayman) I L.P. · CIK 0001787092 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,273,420 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Upon the closing of the Issuer's initial public offering, each share of Series B Preferred Stock and Series C Preferred Stock automatically converted into one share of the Issuer's Common Stock. Each of the Series B Preferred Stock and Series C Preferred Stock had no expiration date. Read SEC document |
| October 20, 2020 Filed Oct 22, 2020 20:12 UTC | Aligos Therapeutics, Inc. ALGS · Entity 7352 | ConversionSeries B-2 convertible Preferred Stock · Derivative | 571,143 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-055562 · doc4.xml · derivative · entry 4 Wellington Biomedical Innovation Master Investors (Cayman) I L.P. · CIK 0001787092 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 571,143 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The shares of series B-1 convertible preferred stock and series B-2 convertible preferred stock shall automatically convert into shares of Common Stock on a one to one basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and have no expiration date. F1 · derivative.exercise_date: The shares of series B-1 convertible preferred stock and series B-2 convertible preferred stock shall automatically convert into shares of Common Stock on a one to one basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and have no expiration date. F1 · derivative.expiration_date: The shares of series B-1 convertible preferred stock and series B-2 convertible preferred stock shall automatically convert into shares of Common Stock on a one to one basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and have no expiration date. Read SEC document |
| October 20, 2020 Filed Oct 22, 2020 20:12 UTC | Aligos Therapeutics, Inc. ALGS · Entity 7352 | ConversionSeries B-1 convertible Preferred Stock · Derivative | 1,335,048 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-055562 · doc4.xml · derivative · entry 3 Wellington Biomedical Innovation Master Investors (Cayman) I L.P. · CIK 0001787092 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,335,048 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The shares of series B-1 convertible preferred stock and series B-2 convertible preferred stock shall automatically convert into shares of Common Stock on a one to one basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and have no expiration date. F1 · derivative.exercise_date: The shares of series B-1 convertible preferred stock and series B-2 convertible preferred stock shall automatically convert into shares of Common Stock on a one to one basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and have no expiration date. F1 · derivative.expiration_date: The shares of series B-1 convertible preferred stock and series B-2 convertible preferred stock shall automatically convert into shares of Common Stock on a one to one basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and have no expiration date. Read SEC document |
| October 20, 2020 Filed Oct 22, 2020 20:12 UTC | Aligos Therapeutics, Inc. ALGS · Entity 7352 | ConversionCommon Stock | 571,143 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-20-055562 · doc4.xml · nonDerivative · entry 2 Wellington Biomedical Innovation Master Investors (Cayman) I L.P. · CIK 0001787092 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,906,191 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The shares of series B-1 convertible preferred stock and series B-2 convertible preferred stock shall automatically convert into shares of Common Stock on a one to one basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and have no expiration date. Read SEC document |
| October 20, 2020 Filed Oct 22, 2020 20:12 UTC | Aligos Therapeutics, Inc. ALGS · Entity 7352 | ConversionCommon Stock | 1,335,048 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-20-055562 · doc4.xml · nonDerivative · entry 1 Wellington Biomedical Innovation Master Investors (Cayman) I L.P. · CIK 0001787092 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,335,048 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The shares of series B-1 convertible preferred stock and series B-2 convertible preferred stock shall automatically convert into shares of Common Stock on a one to one basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and have no expiration date. Read SEC document |
| September 29, 2020 Filed Sep 29, 2020 20:48 UTC | PMV Pharmaceuticals, Inc. PMVP · Entity 7062 | ConversionSeries D Preferred Stock · Derivative | 760,267 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-052351 · doc4.xml · derivative · entry 2 Wellington Biomedical Innovation Master Investors (Cayman) I L.P. · CIK 0001787092 · Former 10% Owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 760,267 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The shares of Series D Preferred Stock automatically converted into shares of Common Stock on a one to one basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and have no expiration date. F1 · derivative.exercise_date: The shares of Series D Preferred Stock automatically converted into shares of Common Stock on a one to one basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and have no expiration date. F1 · derivative.expiration_date: The shares of Series D Preferred Stock automatically converted into shares of Common Stock on a one to one basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and have no expiration date. Read SEC document |
| September 29, 2020 Filed Sep 29, 2020 20:48 UTC | PMV Pharmaceuticals, Inc. PMVP · Entity 7062 | ConversionCommon Stock | 760,267 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-20-052351 · doc4.xml · nonDerivative · entry 1 Wellington Biomedical Innovation Master Investors (Cayman) I L.P. · CIK 0001787092 · Former 10% Owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 760,267 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The shares of Series D Preferred Stock automatically converted into shares of Common Stock on a one to one basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and have no expiration date. Read SEC document |
| September 21, 2020 Filed Sep 23, 2020 22:56 UTC | Dyne Therapeutics, Inc. DYN · Entity 3948 | ConversionSeries B Preferred Stock · Derivative | 5,336,179 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-20-026172 · doc4.xml · derivative · entry 2 Wellington Biomedical Innovation Master Investors (Cayman) I L.P. · CIK 0001787092 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,608,785 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: On September 21, 2020, the Series B Preferred Stock automatically converted into Common Stock on a 3.3169-for-one basis without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date. F1 · derivative.exercise_date: On September 21, 2020, the Series B Preferred Stock automatically converted into Common Stock on a 3.3169-for-one basis without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date. F1 · derivative.expiration_date: On September 21, 2020, the Series B Preferred Stock automatically converted into Common Stock on a 3.3169-for-one basis without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date. Read SEC document |
| September 21, 2020 Filed Sep 23, 2020 22:56 UTC | Dyne Therapeutics, Inc. DYN · Entity 3948 | ConversionCommon Stock | 1,608,785 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-20-026172 · doc4.xml · nonDerivative · entry 1 Wellington Biomedical Innovation Master Investors (Cayman) I L.P. · CIK 0001787092 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,608,785 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: On September 21, 2020, the Series B Preferred Stock automatically converted into Common Stock on a 3.3169-for-one basis without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date. Read SEC document |
| August 25, 2020 Filed Aug 27, 2020 20:12 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | ConversionSeries C Preferred Stock · Derivative | 1,529,847 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-20-023500 · doc4.xml · derivative · entry 2 Wellington Biomedical Innovation Master Investors (Cayman) I L.P. · CIK 0001787092 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 959,211 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Upon the closing of the Issuer's initial public offering, each share of Series C Preferred Stock automatically converted into shares of the Issuer's Common Stock on a 1.5949-for-one basis. The Series C Preferred Stock had no expiration date. F1 · derivative.exercise_date: Upon the closing of the Issuer's initial public offering, each share of Series C Preferred Stock automatically converted into shares of the Issuer's Common Stock on a 1.5949-for-one basis. The Series C Preferred Stock had no expiration date. F1 · derivative.expiration_date: Upon the closing of the Issuer's initial public offering, each share of Series C Preferred Stock automatically converted into shares of the Issuer's Common Stock on a 1.5949-for-one basis. The Series C Preferred Stock had no expiration date. Read SEC document |
| August 25, 2020 Filed Aug 27, 2020 20:12 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | ConversionCommon Stock | 959,211 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-20-023500 · doc4.xml · nonDerivative · entry 1 Wellington Biomedical Innovation Master Investors (Cayman) I L.P. · CIK 0001787092 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 959,211 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Upon the closing of the Issuer's initial public offering, each share of Series C Preferred Stock automatically converted into shares of the Issuer's Common Stock on a 1.5949-for-one basis. The Series C Preferred Stock had no expiration date. Read SEC document |
| July 28, 2020 Filed Jul 31, 2020 00:08 UTC | Nurix Therapeutics, Inc. NRIX · Entity 1156 | ConversionSeries D Preferred Stock · Derivative | 784,313 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-20-020811 · doc4.xml · derivative · entry 2 Wellington Biomedical Innovation Master Investors (Cayman) I L.P. · CIK 0001787092 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 784,313 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Immediately prior to the closing of the Issuer's initial public offering, each share of Series D Preferred Stock automatically converted into one share of Common Stock of the Issuer. The Series D Preferred Stock had no expiration date. F1 · derivative.exercise_date: Immediately prior to the closing of the Issuer's initial public offering, each share of Series D Preferred Stock automatically converted into one share of Common Stock of the Issuer. The Series D Preferred Stock had no expiration date. F1 · derivative.expiration_date: Immediately prior to the closing of the Issuer's initial public offering, each share of Series D Preferred Stock automatically converted into one share of Common Stock of the Issuer. The Series D Preferred Stock had no expiration date. Read SEC document |
| July 28, 2020 Filed Jul 31, 2020 00:08 UTC | Nurix Therapeutics, Inc. NRIX · Entity 1156 | ConversionCommon Stock | 784,313 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-20-020811 · doc4.xml · nonDerivative · entry 1 Wellington Biomedical Innovation Master Investors (Cayman) I L.P. · CIK 0001787092 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 784,313 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Immediately prior to the closing of the Issuer's initial public offering, each share of Series D Preferred Stock automatically converted into one share of Common Stock of the Issuer. The Series D Preferred Stock had no expiration date. Read SEC document |
| June 23, 2020 Filed Jun 25, 2020 17:48 UTC | Forma Therapeutics Holdings, Inc. FMTX · Entity 123059 | ConversionSeries D Convertible Preferred Stock · Derivative | 5,359,344 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-20-038965 · doc4.xml · derivative · entry 3 Wellington Biomedical Innovation Master Investors (Cayman) I L.P. · CIK 0001787092 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,252,913 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: On June 23, 2020, the Series D Convertible Preferred Stock automatically converted into common stock on a 4.2775-for-one basis without payment of further consideration upon the closing of the initial public offering of the Issuer's common stock. The shares had no expiration date. F1 · kind: On June 23, 2020, the Series D Convertible Preferred Stock automatically converted into common stock on a 4.2775-for-one basis without payment of further consideration upon the closing of the initial public offering of the Issuer's common stock. The shares had no expiration date. F1 · price: On June 23, 2020, the Series D Convertible Preferred Stock automatically converted into common stock on a 4.2775-for-one basis without payment of further consideration upon the closing of the initial public offering of the Issuer's common stock. The shares had no expiration date. F1 · derivative.exercise_date: On June 23, 2020, the Series D Convertible Preferred Stock automatically converted into common stock on a 4.2775-for-one basis without payment of further consideration upon the closing of the initial public offering of the Issuer's common stock. The shares had no expiration date. F1 · derivative.expiration_date: On June 23, 2020, the Series D Convertible Preferred Stock automatically converted into common stock on a 4.2775-for-one basis without payment of further consideration upon the closing of the initial public offering of the Issuer's common stock. The shares had no expiration date. Read SEC document |
| June 23, 2020 Filed Jun 25, 2020 17:48 UTC | Forma Therapeutics Holdings, Inc. FMTX · Entity 123059 | PurchaseCommon Stock | 1,000,000 | $20.00 | $20,000,000.00 |
DisclosureSEC source: 0001209191-20-038965 · doc4.xml · nonDerivative · entry 2 Wellington Biomedical Innovation Master Investors (Cayman) I L.P. · CIK 0001787092 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,252,913 Read SEC document |
| June 23, 2020 Filed Jun 25, 2020 17:48 UTC | Forma Therapeutics Holdings, Inc. FMTX · Entity 123059 | ConversionCommon Stock | 1,252,913 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-20-038965 · doc4.xml · nonDerivative · entry 1 Wellington Biomedical Innovation Master Investors (Cayman) I L.P. · CIK 0001787092 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,252,913 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: On June 23, 2020, the Series D Convertible Preferred Stock automatically converted into common stock on a 4.2775-for-one basis without payment of further consideration upon the closing of the initial public offering of the Issuer's common stock. The shares had no expiration date. F1 · price: On June 23, 2020, the Series D Convertible Preferred Stock automatically converted into common stock on a 4.2775-for-one basis without payment of further consideration upon the closing of the initial public offering of the Issuer's common stock. The shares had no expiration date. Read SEC document |
| June 16, 2020 Filed Jun 18, 2020 22:02 UTC | Generation Bio Co. GBIO · Entity 67174 | ConversionSeries C Preferred Stock · Derivative | 1,788,460 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-20-017119 · doc4.xml · derivative · entry 3 Wellington Biomedical Innovation Master Investors (Cayman) I L.P. · CIK 0001787092 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,012,546 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: On June 16, 2020, the Series C Preferred Stock automatically converted into Common Stock on a 1.7663-for-one basis without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date. F1 · derivative.exercise_date: On June 16, 2020, the Series C Preferred Stock automatically converted into Common Stock on a 1.7663-for-one basis without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date. F1 · derivative.expiration_date: On June 16, 2020, the Series C Preferred Stock automatically converted into Common Stock on a 1.7663-for-one basis without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date. Read SEC document |
| June 16, 2020 Filed Jun 18, 2020 22:02 UTC | Generation Bio Co. GBIO · Entity 67174 | PurchaseCommon Stock | 1,100,000 | $19.00 | $20,900,000.00 |
DisclosureSEC source: 0000899243-20-017119 · doc4.xml · nonDerivative · entry 2 Wellington Biomedical Innovation Master Investors (Cayman) I L.P. · CIK 0001787092 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,112,546 Read SEC document |
| June 16, 2020 Filed Jun 18, 2020 22:02 UTC | Generation Bio Co. GBIO · Entity 67174 | ConversionCommon Stock | 1,012,546 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-20-017119 · doc4.xml · nonDerivative · entry 1 Wellington Biomedical Innovation Master Investors (Cayman) I L.P. · CIK 0001787092 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,012,546 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: On June 16, 2020, the Series C Preferred Stock automatically converted into Common Stock on a 1.7663-for-one basis without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date. Read SEC document |
| February 03, 2020 Filed Feb 5, 2020 23:06 UTC | Black Diamond Therapeutics, Inc. BDTX · Entity 6669 | ConversionSeries C Preferred Stock · Derivative | 1,713,541 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-20-003374 · doc4.xml · derivative · entry 2 Wellington Biomedical Innovation Master Investors (Cayman) I L.P. · CIK 0001787092 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 568,185 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Upon the closing of the Issuer's initial public offering, all shares of Series C Preferred Stock automatically converted into shares of Common Stock of the Issuer on a one-for-3.01581 basis. The Series C Preferred Stock had no expiration date. F1 · derivative.exercise_date: Upon the closing of the Issuer's initial public offering, all shares of Series C Preferred Stock automatically converted into shares of Common Stock of the Issuer on a one-for-3.01581 basis. The Series C Preferred Stock had no expiration date. F1 · derivative.expiration_date: Upon the closing of the Issuer's initial public offering, all shares of Series C Preferred Stock automatically converted into shares of Common Stock of the Issuer on a one-for-3.01581 basis. The Series C Preferred Stock had no expiration date. Read SEC document |
| February 03, 2020 Filed Feb 5, 2020 23:06 UTC | Black Diamond Therapeutics, Inc. BDTX · Entity 6669 | ConversionCommon Stock | 568,185 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-20-003374 · doc4.xml · nonDerivative · entry 1 Wellington Biomedical Innovation Master Investors (Cayman) I L.P. · CIK 0001787092 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 568,185 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Upon the closing of the Issuer's initial public offering, all shares of Series C Preferred Stock automatically converted into shares of Common Stock of the Issuer on a one-for-3.01581 basis. The Series C Preferred Stock had no expiration date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.